{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:11:36Z","timestamp":1792519896205,"version":"4.5.0"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Gulf Cooperation Council (GCC) countries are undergoing a critical transformation in their healthcare systems. This empowers them to address the rising burden of complex diseases, including rare diseases, cancer, neurological disorders, and immunological illnesses, which involve a high cost of therapy. A strategic shift from volume- to value-based healthcare (VBH) emphasizes sustainability, enhanced accessibility, and improved health outcomes through innovation. GCC\u2019s healthcare is marked by universal coverage and a shifting landscape of public-private partnerships. Rising pharmaceutical costs, especially for specialty drugs, continue to challenge budget sustainability. VBH offers a strategy to align healthcare expenditure with patient outcomes. This framework is supported by global and regional models such as managed entry agreements (MEAs), multi-criteria decision analysis, and real-world evidence (RWE). These models provide guidance for reimbursement strategies and support decision-making regarding high-value treatments. The GCC nations are also progressing towards policy discussion, but face challenges related to infrastructure, regulation, and workforce capacity. The Department of Health (DOH) in Abu Dhabi, which is a governmental health authority in the United Arab Emirates, has officially established a dedicated HTA unit to evaluate and assess new health technologies for evidence-informed decision making. This review highlights specialty care priorities and proposes target strategies such as expanding genetic databases, implementing screening programs, and establishing risk-sharing agreements to improve affordability, particularly for rare diseases. A consensus-driven phased roadmap for GCC-wide VBH adoption is recommended. This includes a focus on MEAs and patient-reported outcome measures, mid-term harmonization of health technology assessments (HTA) and RWE development as well as long-term establishment of digital ecosystems and value-based pricing platforms. Equitable and collaborative policies will be essential to achieving sustainable and inclusive healthcare systems across the GCC.<\/jats:p>","DOI":"10.3389\/fpubh.2025.1667846","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:26:23Z","timestamp":1762323983000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Driving the future of value-based healthcare in the Gulf Cooperation Council: a roadmap for achieving sustainable access to specialty pharmaceuticals"],"prefix":"10.3389","volume":"13","author":[{"given":"Anas","family":"Hamad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Jedai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ojeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrazaq Sheikh","family":"Al-Jazairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"AlAssy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazed S.","family":"AlRuthia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waiel","family":"Al Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer","family":"Almudaiheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouza","family":"Alsaadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alagil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmohsin","family":"Marghalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Al Hashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah O.","family":"AlShehry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Alblooshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtisam","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleine Bejjani","family":"Moukarzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Albalushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"El-Sheashaey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Aseeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Alenezy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathea","family":"Adheir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Aloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab","family":"Alnoaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A.","family":"Alnaqbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"101012","DOI":"10.1016\/j.vhri.2024.101012","article-title":"Consensus-based recommendations for the implementation of health technology assessment in the United Arab Emirates","volume":"43","author":"Alnaqbi","year":"2024","journal-title":"Value Health Regional Issues"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1510401","DOI":"10.3389\/fpubh.2025.1510401","article-title":"Healthcare systems and health economics in GCC countries: informing decision-makers from the perspective of the Gulf health economics association","volume":"13","author":"AlRuthia","year":"2025","journal-title":"Front Public Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1509501","DOI":"10.1155\/2020\/1509501","article-title":"Epidemiology of thalassemia in gulf cooperation council countries: a systematic review","volume":"2020","author":"Abu-Shaheen","year":"2020","journal-title":"Biomed Res Int"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/17474086.2022.2132225","article-title":"Sickle cell disease in gulf cooperation council countries: a systematic review","volume":"15","author":"Abu-Shaheen","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.31014\/aior.1994.04.03.185","article-title":"The public Institute of Applied Education and Training (Kuwait). Does spending more on healthcare yields higher life expectancy? A case study on gulf cooperation council countries","volume":"4","author":"AlSaied","year":"2021","journal-title":"JHMS"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0273040","DOI":"10.1371\/journal.pone.0273040","article-title":"Exploring healthcare providers\u2019 experiences with specialty medication and limited distribution networks","volume":"17","author":"Peter","year":"2022","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40273-014-0196-0","article-title":"A review of approaches for the Management of Specialty Pharmaceuticals in the United States","volume":"32","author":"Patel","year":"2014","journal-title":"PharmacoEconomics"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e1586","DOI":"10.7759\/cureus.1586","article-title":"Health Care in Gulf Cooperation Council Countries: a review of challenges and opportunities","volume":"9","author":"Khoja","year":"2017","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.36401\/JQSH-23-1","article-title":"Overview of procurement and reimbursement of pharmaceuticals in Saudi Arabia, United Arab Emirates, Qatar, and Egypt: challenges and opportunities","volume":"6","author":"Hamad","year":"2023","journal-title":"Glob J Quality Safety Healthcare"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.18553\/jmcp.2021.27.9.1198","article-title":"Evaluation of financial outcomes under a value-based payment program for community pharmacies","volume":"27","author":"Doucette","year":"2021","journal-title":"JMCP"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e090344","DOI":"10.1136\/bmjopen-2024-090344","article-title":"Thresholds for the value judgement of health technologies in the United Arab Emirates: a consensus approach through voting sessions","volume":"14","author":"Aldallal","year":"2024","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1017\/S0266462324004744","article-title":"Road toward institutionalizing health technology assessment in the emirate of Abu Dhabi: the role of evidence-informed deliberative processes","volume":"40","author":"Bijlmakers","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14737167.2018.1474102","article-title":"Health technology assessment in Saudi Arabia","volume":"18","author":"Al-Aqeel","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44162-022-00004-5","article-title":"The impact of consanguinity on human health and disease with an emphasis on rare diseases","volume":"1","author":"Temaj","year":"2022","journal-title":"J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e008670","DOI":"10.1136\/bmjgh-2022-008670","article-title":"The case for investing in the prevention and control of non-communicable diseases in the six countries of the Gulf cooperation council: an economic evaluation","volume":"7","author":"Elmusharaf","year":"2022","journal-title":"BMJ Glob Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jtumed.2024.07.009","article-title":"Burden of non-communicable diseases in health Council of Gulf Cooperation (GCC) countries","volume":"19","author":"Alqadasi","year":"2024","journal-title":"J Taibah Univ Med Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e70141","DOI":"10.1002\/cam4.70141","article-title":"The current and future cancer burden in the Gulf cooperation council (GCC) countries","volume":"13","author":"Alessy","year":"2024","journal-title":"Cancer Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jtumed.2024.07.008","article-title":"Conceptualization and establishment of value-based healthcare in Saudi Arabia: a scoping review","volume":"19","author":"Hariri","year":"2024","journal-title":"J Taibah Univ Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2449051","DOI":"10.1080\/20523211.2024.2449051","article-title":"Transforming healthcare: Saudi Arabia\u2019s vision 2030 healthcare model","volume":"18","author":"Suleiman","year":"2025","journal-title":"J Pharm Policy Pract"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jsps.2020.12.005","article-title":"Cancer Management in Saudi Arabia: recommendations by the Saudi oncology HeAlth economics ExpeRt GrouP (SHARP)","volume":"29","author":"Alkhudair","year":"2021","journal-title":"Saudi Pharm J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.3390\/ijerph20064732","article-title":"Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges","volume":"20","author":"Adachi","year":"2023","journal-title":"IJERPH"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/healthcare10112125","article-title":"Fighting Cancer around the world: a framework for action","volume":"10","author":"Horgan","year":"2022","journal-title":"Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"100163","DOI":"10.1016\/j.aggp.2025.100163","article-title":"Advancing life expectancy in Saudi Arabia: insights from global best practices","volume":"2","author":"Alosaimi","year":"2025","journal-title":"Arch Gerontol Geriat Plus"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.imu.2022.101097","article-title":"The role of the COVID-19 pandemic in expediting digital health-care transformation: Saudi Arabia\u2019s experience","volume":"33","author":"Alkhalifah","year":"2022","journal-title":"Inform Med Unlocked"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-022-00336-0","article-title":"Promise of real-world evidence for patient centricity in gulf cooperation council countries: call to action","volume":"10","author":"Farghaly","year":"2023","journal-title":"Drugs - Real World Outcomes"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/su16010198","article-title":"Sustainable healthcare resilience: disaster preparedness in Saudi Arabia\u2019s Eastern Province hospitals","volume":"16","author":"AlDulij","year":"2023","journal-title":"Sustainability"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1017\/S0266462323001150","article-title":"OP102 towards universal health coverage: health technology assessment roadmap development in the emirate of Abu Dhabi involving the whole ecosystem","volume":"39","author":"Alsaeedi","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-981-99-6794-0_5","article-title":"A proposal for Cancer control plan in the UAE","volume-title":"Cancer Care in the United Arab Emirates","author":"Al-Shamsi","year":"2024"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/healthcare12030315","article-title":"Healthcare quality from the perspective of patients in gulf cooperation council countries: a systematic literature review","volume":"12","author":"Alsubahi","year":"2024","journal-title":"Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12913-022-08981-5","article-title":"Applying value-based strategies to accelerate access to novel cancer medications: guidance from the oncology health economics expert panel in Qatar (Q-OHEP)","volume":"23","author":"Hamad","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jval.2017.11.003","article-title":"Building synergy between regulatory and HTA agencies beyond processes and procedures\u2014can we effectively align the evidentiary requirements? A survey of stakeholder perceptions","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"key":"ref32","year":"2035"},{"key":"ref33","year":"2021"},{"key":"ref34","year":"2016"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archinte.158.15.1596","article-title":"Comparing generalist and specialty care: discrepancies, deficiencies, and excesses","volume":"158","author":"Donohoe","year":"1998","journal-title":"Arch Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.25122\/jml-2021-0070","article-title":"Transformation of health care and the new model of care in Saudi Arabia: kingdom\u2019s vision 2030","volume":"14","author":"Chowdhury","year":"2021","journal-title":"J Med Life"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.54254\/2753-8818\/21\/20230904","article-title":"Current situation and future of gene therapy for rare diseases","volume":"21","author":"Huang","year":"2023","journal-title":"TNS"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1089\/hum.2023.152","article-title":"Advances and challenges in the development of gene therapy medicinal products for rare diseases","volume":"34","author":"Bueren","year":"2023","journal-title":"Hum Gene Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"102302","DOI":"10.1016\/j.japh.2024.102302","article-title":"Implementation of a specialty pharmacy in an ambulatory care setting in Saudi Arabia: patient experience and operational outcomes","volume":"65","author":"Al-Jazairi","year":"2025","journal-title":"J Am Pharm Assoc"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/sjcp.sjcp_39_24","article-title":"Leveraging HEOR services for drug development and market access in the GCC","volume":"3","author":"Sabbagh Dit Hawasli","year":"2024","journal-title":"Saudi J Clin Pharm"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1161\/CIRCULATIONAHA.114.010393","article-title":"Will bundled payments change health care?: examining the evidence thus far in cardiovascular care","volume":"131","author":"Shih","year":"2015","journal-title":"Circulation"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12961-024-01260-1","article-title":"Can integrated care interventions strengthen primary care and improve outcomes for patients with chronic diseases? A systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2025","journal-title":"Health Res Policy Sys"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1715536","DOI":"10.1080\/20016689.2020.1715536","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","volume":"8","author":"J\u00f8rgensen","year":"2020","journal-title":"J Market Access Health Policy"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.vhri.2023.05.002","article-title":"Prioritizing outcome measures for value-based healthcare: physicians\u2019 perspectives in Saudi Arabia","volume":"37","author":"Abdalla","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1517\/14656566.2015.1046837","article-title":"Should patients in need be given access to experimental drugs?","volume":"16","author":"Caplan","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13023-015-0306-x","article-title":"Compassionate use of orphan drugs","volume":"10","author":"Hyry","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/ijp.IJP_665_20","article-title":"Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations","volume":"52","author":"Goyal","year":"2020","journal-title":"Indian J Pharm"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3332\/ecancer.2018.823","article-title":"Risk-sharing agreements, present and future","volume":"12","author":"Gon\u00e7alves","year":"2018","journal-title":"ecancermedicalscience"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s12325-015-0233-1","article-title":"The budget impact of biosimilar infliximab (Remsima\u00ae) for the treatment of autoimmune diseases in five European countries","volume":"32","author":"Jha","year":"2015","journal-title":"Adv Ther"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e2418800","DOI":"10.1001\/jamanetworkopen.2024.18800","article-title":"Cost-effectiveness of Biosimilars vs Leflunomide in patients with rheumatoid arthritis","volume":"7","author":"Peng","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jaip.2020.12.036","article-title":"Biologic therapy in allergy practice: a new era in treatment has begun","volume":"9","author":"Wu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/CEOR.S404175","article-title":"Biosimilars adoption: recognizing and removing the RoadBlocks","volume":"15","author":"Niazi","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: translating evidence into policy","volume":"19","author":"Feigin","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s44197-025-00385-y","article-title":"Advancing health through sustainable development goals\u2013Saudi Arabia\u2019s mid-journey progress and insights","volume":"15","author":"Alarifi","year":"2025","journal-title":"J Epidemiol Glob Health"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"01","DOI":"10.14336\/AD.2024.1071","article-title":"The expanding burden of neurodegenerative diseases: an unmet medical and social need","volume":"16","author":"Wang","year":"2024","journal-title":"Aging Dis"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab \u2014 binding profiles to different forms of amyloid-Beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"102158","DOI":"10.1016\/j.msard.2020.102158","article-title":"Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS","volume":"43","author":"Vermersch","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","article-title":"Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis","volume":"90","author":"Kalincik","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e00601","DOI":"10.1016\/j.neurot.2025.e00601","article-title":"Progressive multiple sclerosis: evaluating current therapies and exploring future treatment strategies","volume":"22","author":"Albelo-Mart\u00ednez","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and Research and Development intensity in the US, 2000-2018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/jama.2024.16911","article-title":"Differential legal protections for biologics vs small-molecule drugs in the US","volume":"332","author":"Wouters","year":"2024","journal-title":"JAMA"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e2233006","DOI":"10.1001\/jamanetworkopen.2022.33006","article-title":"Monthly cost-sharing limits and out-of-pocket costs for commercially insured patients in the US","volume":"5","author":"Shafer","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jama.2024.13162","article-title":"Patient assistance programs\u2014a new era of law and policy","volume":"332","author":"Daval","year":"2024","journal-title":"JAMA"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"862712","DOI":"10.3389\/fcomp.2022.862712","article-title":"Editorial: The role of real world evidence (RWE) for digital health","volume":"4","author":"Kyriazakos","year":"2022","journal-title":"Front Comput Sci"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1128\/jcm.29.12.2794-2797.1991","article-title":"Serotyping of Canadian isolates of Treponema hyodysenteriae and description of two new serotypes","volume":"29","author":"Li","year":"1991","journal-title":"J Clin Microbiol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e64995","DOI":"10.7759\/cureus.64995","article-title":"Pregnancy outcomes among women with sickle cell disease in Bahrain: a case-control study","volume":"16","author":"Marhoon","year":"2024","journal-title":"Cureus"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4103\/0256-4947.65256","article-title":"Public awareness of sickle cell disease in Bahrain","volume":"30","author":"Al Arrayed","year":"2010","journal-title":"Ann Saudi Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1470-2045(21)00752-X","article-title":"Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study","volume":"23","author":"Saad","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1177204","DOI":"10.3389\/fgene.2023.1177204","article-title":"Spectrum of genetic disorders and gene variants in the United Arab Emirates national population: insights from the CTGA database","volume":"14","author":"Bizzari","year":"2023","journal-title":"Front Genet"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e2017013","DOI":"10.4084\/MJHID.2017.013","article-title":"Alloimmunization in patients with sickle cell disease and thalassaemia: experience of single centre from Oman","volume":"9","author":"Pathare","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12687-020-00500-5","article-title":"Improving diagnostics of rare genetic diseases with NGS approaches","volume":"12","author":"Vink\u0161el","year":"2021","journal-title":"J Community Genet"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jval.2024.12.009","article-title":"Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions","volume":"28","author":"Gentilini","year":"2025","journal-title":"Value Health"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40271-020-00493-w","article-title":"The use of patient-reported outcome measures in rare diseases and implications for health technology assessment","volume":"14","author":"Whittal","year":"2021","journal-title":"Patient"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"07","DOI":"10.33545\/26647591.2024.v6.i1a.73","article-title":"Regulatory requirements: the orphan drugs in various countries","volume":"6","author":"Karunanidhi","year":"2024","journal-title":"Int J Pharm Clin Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13023-023-02853-9","article-title":"Together4RD position statement on collaboration between European reference networks and industry","volume":"18","author":"Hedley","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front Oncol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.yapd.2019.04.001","article-title":"Gene therapy","volume":"66","author":"Steffin","year":"2019","journal-title":"Adv Pediatr Infect Dis"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/hum.2023.186","article-title":"A review of the cost-effectiveness evidence for FDA-approved cell and gene therapies","volume":"35","author":"Abuloha","year":"2024","journal-title":"Hum Gene Ther"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1016\/j.jval.2021.11.711","article-title":"POSB217 is the gene therapy revolution sustainable and affordable?","volume":"25","author":"Orchard","year":"2022","journal-title":"Value Health"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1089\/hum.2023.127","article-title":"Realizing the potential of gene therapies for rare and ultra-rare inherited diseases","volume":"34","author":"Booth","year":"2023","journal-title":"Hum Gene Ther"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000529168","article-title":"Drug shortage concepts among stakeholders in Saudi Arabia","volume":"3","author":"Almutairi","year":"2023","journal-title":"Saudi J Health Syst Res"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","article-title":"Real-world data: a brief review of the methods, applications, challenges and opportunities","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5089\/9798400291449.087","article-title":"Digital transformation in the Gulf cooperation council economies","volume":"2025","author":"Bi","year":"2025","journal-title":"Depart Papers"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.6007\/IJARBSS\/v4-i12\/1326","article-title":"Management of healthcare in the Gulf cooperation council (GCC) countries with special reference to Saudi Arabia","volume":"4","author":"Ram","year":"2014","journal-title":"IJARBSS"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1002\/hpm.2213","article-title":"Financing healthcare in gulf cooperation council countries: a focus on Saudi Arabia","volume":"29","author":"Alkhamis","year":"2014","journal-title":"Health Planning Manag"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jval.2012.06.015","article-title":"Multiple criteria decision analysis for health technology assessment","volume":"15","author":"Thokala","year":"2012","journal-title":"Value Health"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12913-019-4081-6","article-title":"Value based competition in health care\u2019s ethical drawbacks and the need for a values-driven approach","volume":"19","author":"Groenewoud","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-90-481-9485-8_16","article-title":"Cost of illness and economic evaluation in rare diseases","volume-title":"Rare diseases epidemiology. Advances in experimental medicine and biology","author":"L\u00f3pez-Bastida","year":"2010"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fpubh.2018.00287","article-title":"Multi-criteria decision analysis (MCDA) models in health technology assessment of orphan drugs\u2014a systematic literature review. Next steps in methodology development?","volume":"6","author":"Baran-Kooiker","year":"2018","journal-title":"Front Public Health"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12913-017-2340-y","article-title":"Centers of excellence in healthcare institutions: what they are and how to assemble them","volume":"17","author":"Elrod","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/13696998.2019.1588737","article-title":"Cost-effectiveness analyses using real-world data: an overview of the literature","volume":"22","author":"Bowrin","year":"2019","journal-title":"J Med Econ"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"101000","DOI":"10.1016\/j.imr.2023.101000","article-title":"Real-world data analysis on effectiveness of integrative therapies: a practical guide to study design and data analysis using healthcare databases","volume":"12","author":"Lee","year":"2023","journal-title":"Integrat Med Res"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1177\/1049909120944868","article-title":"COVID-19 pandemic response: development of outpatient palliative care toolkit based on narrative communication","volume":"37","author":"Roberts","year":"2025","journal-title":"Am J Hosp Palliat Med"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"205520762211177","DOI":"10.1177\/20552076221117742","article-title":"Digital health transformation in Saudi Arabia: a cross-sectional analysis using healthcare information and management systems society\u2019 digital health indicators","volume":"8","author":"Al-Kahtani","year":"2022","journal-title":"Digital Health"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1744-8603-7-39","article-title":"A win-win solution?: a critical analysis of tiered pricing to improve access to medicines in developing countries","volume":"7","author":"Moon","year":"2011","journal-title":"Glob Health"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e230093","DOI":"10.57264\/cer-2023-0093","article-title":"Flexibility in assessment of rare disease technologies via NICE\u2019S single technology appraisal route: a thematic analysis","volume":"12","author":"Hale","year":"2023","journal-title":"J Comp Eff Res"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","article-title":"Managed entry agreements: policy analysis from the European perspective","volume":"23","author":"Dabbous","year":"2020","journal-title":"Value Health"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jval.2019.06.014","article-title":"Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward","volume":"22","author":"Baltussen","year":"2019","journal-title":"Value Health"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.vhri.2023.12.005","article-title":"A step toward the development of the first National Multi-Criteria Decision Analysis Framework to support healthcare decision making in Saudi Arabia","volume":"41","author":"Al-Jedai","year":"2024","journal-title":"Value Health Regional Issues"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55215","article-title":"Development of the emirates multi-criteria decision analysis tool for orphan drugs","author":"Alnaqbi","year":"2024","journal-title":"Cureus"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40545-019-0171-4","article-title":"Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait","volume":"12","author":"Abdullah","year":"2019","journal-title":"J Pharm Policy Pract"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fpubh.2016.00214","article-title":"Multi-criteria decision analysis for assessment and appraisal of orphan drugs","volume":"4","author":"Iskrov","year":"2016","journal-title":"Front Public Health"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3390\/cancers16112017","article-title":"Genomic newborn screening for pediatric cancer predisposition syndromes: a holistic approach","volume":"16","author":"Linga","year":"2024","journal-title":"Cancer"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41598-022-05296-7","article-title":"Genetic data sharing and artificial intelligence in the era of personalized medicine based on a cross-sectional analysis of the Saudi human genome program","volume":"12","author":"Alrefaei","year":"2022","journal-title":"Sci Rep"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/humu.24278","article-title":"Actionable genomic variants in 6045 participants from the Qatar genome program","volume":"42","author":"Elfatih","year":"2021","journal-title":"Hum Mutat"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1514098","DOI":"10.3389\/fpubh.2025.1514098","article-title":"Implementing value-based healthcare: a scoping review of key elements, outcomes, and challenges for sustainable healthcare systems","volume":"13","author":"Khalil","year":"2025","journal-title":"Front Public Health"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jval.2012.05.006","article-title":"Challenges in the development and reimbursement of personalized medicine\u2014payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group","volume":"15","author":"Faulkner","year":"2012","journal-title":"Value Health"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.3390\/su16083277","article-title":"Transforming healthcare in Saudi Arabia: a comprehensive evaluation of vision 2030\u2019s impact","volume":"16","author":"Mani","year":"2024","journal-title":"Sustainability"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/M18-0342","article-title":"Value-based health care meets cost-effectiveness analysis","volume":"169","author":"Tsevat","year":"2018","journal-title":"Ann Intern Med"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"986","DOI":"10.46799\/jss.v3i5.414","article-title":"Key success in the transformation from volume-based to value-based healthcare: a scoping review","volume":"3","author":"Gunawan","year":"2022","journal-title":"JSS"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"438","DOI":"10.17749\/2070-4909\/farmakoekonomika.2020.042","article-title":"Concept of value-based healthcare","volume":"13","author":"Musina","year":"2021","journal-title":"Farmako\u00e8konomika"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/1357633X16647894","article-title":"Systematic thematic review of e-health research in the Gulf cooperation council (Arabian gulf): Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates","volume":"23","author":"Weber","year":"2017","journal-title":"J Telemed Telecare"},{"key":"ref113","first-page":"13","article-title":"Value-driven digital transformation in health and medical care","volume-title":"Interactive process mining in healthcare. Health informatics","author":"Seoane","year":"2021"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.3390\/ijerph20043407","article-title":"Digital transformation in healthcare: technology acceptance and its applications","volume":"20","author":"Stoumpos","year":"2023","journal-title":"IJERPH"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/07435800.2024.2341146","article-title":"Digital health in diabetes and cardiovascular disease","volume":"49","author":"Avoke","year":"2024","journal-title":"Endocr Res"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"20174","DOI":"10.1038\/s41746-017-0004-2","article-title":"Population measurement for health systems","volume":"1","author":"Schatz","year":"2018","journal-title":"NPJ Digital Med"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/03007995.2024.2433245","article-title":"The tango to modern collaboration and patient-centric value generation in health care \u2013 a real-world guide from practitioners for practitioners: a field analysis on value-based health care of 12 leading institutions worldwide","volume":"41","author":"Hefti","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nm1095-986","article-title":"Confusion reigns over compassionate use of AIDS drug","volume":"1","author":"Tastemain","year":"1995","journal-title":"Nat Med"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1108\/LHS-01-2024-0012","article-title":"Excellence in healthcare: nurturing servant leadership, fostering collaborative culture and promoting social sustainability in the UAE \u2013 strategies for transformation","volume":"37","author":"Upadhyay","year":"2024","journal-title":"LHS"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s44197-022-00076-y","article-title":"A new era of National Guideline Development in Saudi Arabia","volume":"12","author":"Memish","year":"2022","journal-title":"J Epidemiol Glob Health"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"48","DOI":"10.47191\/ijmscrs\/v3-i12-48","article-title":"Saudi Arabia\u2019s new care model and the transformation of health care kingdom\u2019s vision 2030","volume":"3","author":"Izzuldeen Ali","year":"2023","journal-title":"IJMSCRS"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2125.2009.03589.x","article-title":"Pharmacoeconomics: NICE\u2019S approach to decision-making","volume":"70","author":"Rawlins","year":"2010","journal-title":"Brit J Clin Pharm"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1089\/tmj.2024.0114","article-title":"The rise of virtual health care: transforming the health care landscape in the Kingdom of Saudi Arabia: a review article","volume":"30","author":"Sheerah","year":"2024","journal-title":"Telemed e-Health"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5430\/ijh.v3n2p78","article-title":"The healthcare system in Saudi Arabia: how can we best move forward with funding to protect equitable and accessible care for all?","volume":"3","author":"Al-Hanawi","year":"2017","journal-title":"IJH"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12961-021-00721-1","article-title":"Barriers and facilitators to conducting economic evaluation studies of gulf cooperation council (GCC) countries: a survey of researchers","volume":"19","author":"Almazrou","year":"2021","journal-title":"Health Res Policy Sys"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/PPA.S416226","article-title":"Comparison of rare and common diseases in the setting of healthcare priorities: evidence of social preferences based on a systematic review","volume":"17","author":"Gu","year":"2023","journal-title":"PPA"},{"key":"ref127","year":"2025"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","article-title":"The future of Biosimilars: maximizing benefits across immune-mediated inflammatory diseases","volume":"80","author":"Kim","year":"2020","journal-title":"Drugs"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1001\/jama.2021.8562","article-title":"A National Goal to advance health equity through value-based payment","volume":"325","author":"Liao","year":"2021","journal-title":"JAMA"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462320000215","article-title":"The new definition of health technology assessment: a milestone in international collaboration","volume":"36","author":"O\u2019Rourke","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N Engl J Med"},{"key":"ref132","author":"Papanicolas","year":"2022"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/JHL.S516159","article-title":"Challenges of healthcare systems in Saudi Arabia to delivering vision 2030: an empirical study from healthcare workers perspectives","volume":"17","author":"Al-Anezi","year":"2025","journal-title":"J Healthcare Leadersh"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3390\/healthcare12242544","article-title":"Healthcare financing in Saudi Arabia: a comprehensive review","volume":"12","author":"Nair","year":"2024","journal-title":"Health"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12961-022-00872-9","article-title":"Noncommunicable diseases and health system responses in Saudi Arabia: focus on policies and strategies. A qualitative study","volume":"20","author":"Hazazi","year":"2022","journal-title":"Health Res Policy Syst"},{"key":"ref136","year":"2020"},{"key":"ref137","year":"2024"},{"key":"ref138","year":"2020"},{"key":"ref139","year":"2025"},{"key":"ref140","year":"2024"},{"key":"ref141","year":"2025"},{"key":"ref142","year":"2025"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1667846\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:26:24Z","timestamp":1762323984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1667846\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":142,"alternative-id":["10.3389\/fpubh.2025.1667846"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1667846","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1667846"}}